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Abstract: Several lines of evidence suggest that the dopaminergic nervous system contributes to methamphetamine 
(METH) dependence, and there is increasing evidence of antagonistic interactions between dopamine and adenosine re-
ceptors in METH abusers. We therefore hypothesized that variations in the A1 adenosine receptor (ADORA1) gene mod-
ify genetic susceptibility to METH dependence/psychosis. In this study, we identified 7 single nucleotide polymorphisms 
(SNPs) in exons and exon-intron boundaries of the ADORA1 gene in a Japanese population. A total of 171 patients and 
229 controls were used for an association analysis between these SNPs and METH dependence/psychosis. No significant 
differences were observed in either the genotypic or allelic frequencies between METH dependent/psychotic patients and 
controls. A global test of differentiation among samples based on haplotype frequencies showed no significant associa-
tion. In the clinical feature analyses, no significant associations were observed among latency of psychosis, prognosis of 
psychosis, and spontaneous relapse. These results suggest that the ADORA1 gene variants may make little or no contribu-
tion to vulnerability to METH dependence/psychosis. 
Keywords: Single nucleotide polymorphism, SNP, variation, human, Japanese, MAP, abuse, dopamine. 
INTRODUCTION 
  Methamphetamine (METH) is a psychomotor stimulant 
with high liability for abuse, and METH abuse has become a 
very serious social problem in Japan [1]. Chronic METH 
abusers have been shown to have persistent dopaminergic 
deficits [2, 3]. Amphetamines are thought to produce their 
stimulant effects mainly via the dopaminergic system [4, 5], 
although other systems may also be involved. Dopamine D1 
and D2 receptors form heterodimeric complexes with adeno-
sine A1 and A2a receptors respectly, which modulate their 
responsiveness [6-9], suggesting that responses to ampheta-
mines may also depend on adenosinergic function. 
  Several lines of evidence suggest that adenosine A1 re-
ceptors play a role in inhibiting the effects of METH. 
Adenosine receptor antagonists potentiate the effects of 
lower METH doses and substitute for the discriminative 
stimulus effects of METH [10, 11]. Adenosine receptor   
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agonists protect against METH-induced neurotoxicity, and 
amphetamine-induced stereotypy and locomotor activity, and 
reduce the acquisition of conditioned place preference in-
duced by amphetamine [12-15]. These results suggest that 
adenosine A1 receptors play important roles in the expres-
sion of METH-induced neurotoxicities and behaviors. 
  To date, however, there has been no association analysis 
between A1 adenosine receptor (ADORA1) gene variants and 
drug addiction. The purpose of this study was (1) to identify 
novel sequence variants in all coding exons as well as exon-
intron boundaries of the ADORA1 gene in Japanese, and (2) 
to investigate whether these polymorphisms and/or haplo-
types were associated with METH dependence/psychosis. 
MATERIALS AND METHODS 
Subjects 
  One-hundred seventy-one unrelated patients with METH 
dependence/psychosis (138 males and 33 females; mean age 
37.5±12.0 years) meeting ICD-10-DCR criteria (F15.2 and 
F15.5) were used as case subjects; they were outpatients or 
inpatients of psychiatric hospitals. The 229 control subjects 
(119 males and 110 females; mean age 41.2±12.3 years) 
were mostly medical staff members who had neither per-138    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kobayashi et al. 
sonal nor familial history of drug dependence or psychotic 
disorders, as verified by a clinical interview. All subjects 
were Japanese, born and living in the northern Kyushu, 
Setouchi, Chukyo, Tokai, and Kanto regions. This study was 
approved by the ethical committees of each institute of the 
Japanese Genetics Initiative for Drug Abuse (JGIDA), and 
all subjects provided written informed consent for the use of 
their DNA samples for this research [16]. After informed 
consent was obtained, blood samples were drawn and   
genomic DNA was extracted by the phenol/chloroform 
method. 
Defining Variants of the ADORA1 Gene 
  Initially, DNA samples from 16 METH depend-
ent/psychotic patients were used to identify nucleotide vari-
ants within the ADORA1 gene (GenBank accession no. 
AC105940). Exon numbers were based on the report by Ren 
and colleagues [17]. Exons 1A, 1B, 2, 3 and exon-intron 
boundaries were amplified by polymerase chain reaction 
(PCR) using a thermal cycler (Astec, Fukuoka, Japan), and 
the products were sequenced in both directions using BigDye 
terminators (Applied Biosystems, Foster City, CA) by an 
ABI Genetic analyzer 3100 (Applied Biosystems). The 
primer sequences used in this study are shown in Table 1. 
  Genotyping of IVS1A+182 (rs56298433) was performed 
by PCR amplification using 2F-2R primers followed by re-
striction enzyme Nla III digestion. Genotyping of 
Exon2+363 (rs10920568) was performed by PCR amplifica-
tion using 4F-4R primers followed by sequencing with the 
same primers. IVS2+35826 (rs5780149) was performed by 
PCR amplification using 5F-9R primers followed by se-
quencing with 5F and 5R primers. Genotyping of Exon3+937 
(rs6427994), Exon3+987 (rs41264025), and Exon3+1064 
(rs16851030) was performed by PCR amplification using 
5F-9R primers followed by sequencing with 7F and 7R 
primers. 
Patient Subgroups 
  For the clinical category analysis, the patients were di-
vided into two subgroups by three different clinical features. 
(A) Latency of psychosis from first METH intake: less than 
3 years or more than 3 years. The course of METH psychosis 
varied among patients, with some patients showing psycho-
sis sooner after the first METH intake, as previously reported 
[16, 18]. Because the median latency was 3 years, this time 
point was used as the cutoff in defining the two groups. (B) 
Duration of psychosis after the last METH intake: transient 
(<1 month) or prolonged (> =1 month). Some patients showed 
continuous psychotic symptoms even after METH discon-
tinuation, as previously reported [16, 18]. Patients with the 
transient type showed a reduction of psychotic symptoms 
within one month after the discontinuation of METH con-
sumption and the beginning of treatment with neuroleptics. 
Patients with the prolonged type showed a psychotic symp-
toms continued for more than one month even after the dis-
continuation of METH consumption and the beginning of 
neuroleptic treatment. (C) Spontaneous relapse: present or 
not. It has been well documented that once METH psychosis 
has developed, patients in the remission phase are liable to 
spontaneous relapse without reconsumption of METH [16, 18]. 
Statistical Analysis 
  The Hardy-Weinberg equilibrium of genotypic frequen-
cies in each SNP was tested by the chi-square test. The level 
of statistical significance was set at = 0.05. The allelic and 
genotypic frequencies of the patient and control groups were 
compared using the chi-square test. Haplotype frequencies 
were calculated by the Arlequin program available from 
http://anthropologie.unige.ch/arlequin [19]. Locus by locus 
linkage disequilibrium (LD) was evaluated by D’ and r
2, 
which were calculated by the haplotype frequencies using 
the appropriate formula in the Excel program. A global test 
of differentiation among samples based on haplotype fre-
quencies was also performed by the Arlequin program. 
RESULTS 
Analysis of the ADORA1 Gene Variants 
  To identify polymorphisms in the ADORA1 gene, exons 
1A, 1B, 2, and 3, and exon-intron boundaries were analyzed 
using genomic DNA from Japanese METH dependent/ 
psychotic subjects. Seven SNPs were identified (Table 2). 
Five out of seven of these SNPs were previously reported by 
Deckert [20]. In the two SNPs, the frequencies of the minor 
Table 1.  Primers Used in this Study 
Exon                       Forward                    Reverse 
Exon1A 1F: TGG  ACT  GGA TGC CTT ATG GCT TAG  1R:  GGC GCA GGA GCT GAG TGA CAA TCG 
  2F:  TCT CAC CCA GTA TCA CTT CCT TTG  2R:  ATC ACA TGG TAC GGC AGA GAC TCA 
Exon1B 3F: AAT  AGG GAG AAA CGC CCC AGC CTT  3R:  AAG CAC CTG TGT GGT CAG GGA AGC 
Exon2 4F:  GGT  AGG AGC TGC ATG TGA CAA GTG  4R:  GCA GAG TGA GGA CTG GAG CAC GAT 
Exon3 5F:  GGC  TGT  CAT  GAA GCA ATG ATG AGA  5R:  CCA GCG ACT TGG CGA TCT TCA GCT 
  6F:  TCT ACC TGG AGG TCT TCT ACC TAA  6R:  CCC TGA AGC TCT GGA CTG CTC ATG 
  7F:  GTG GTC CCT CCA CTA GGA GTT AAC  7R:  ACA GGT AAT TAC ACT CCA AGG CTC 
  8F:  CTG ATA TTT GCT GGA GTG CTG GCT  8R:  ACA CCT GCA ACA GAG CTT CCA AAG 
  9F:  CCT TGC TGT CAT GTG AAT CCC TCA  9R:  CAA GAG GAA GAT GCC AAT GGG AGA ADORA1 Gene Association with METH Abuse  Current Neuropharmacology, 2011, Vol. 9, No. 1    139 
alleles differed between our patients and those of Deckert. In 
the Exon2+363 (rs10920568) SNP, the G allele was present 
in 15.5% of our Japanese controls (Table 3) and 36.9% of the 
German controls [20]. In the Exon3+1064 (rs16851030) 
SNP, the T allele was present in 35.8% of our Japanese con-
trols and 1.2% of the German controls [20]. These differ-
ences were suggested to be related to the difference in   
ethnicity between the two cohorts. One SNP, Exon2+363 
(rs10920568), was a synonymous mutation (Ala to Ala)   
(Table 2). All the other SNPs were located either in the in-
trons or an untranslated region in the exon 3. Two SNPs 
(Exon3+937 (rs6427994) and Exon3+1454 (rs11315020)) 
were in linkage disequilibrium (LD) in the sense that the 
genotypic patterns of the 16 samples examined were the 
same, representing Exon3+937 (rs6427994) for these two 
SNPs. IVS1A+182 (rs56298433), Exon2+363 (rs10920568), 
IVS2+35826 (rs5780149), Exon3+937 (rs6427994), Exon3+ 
987 (rs41264025), and Exon3+1064 (rs16851030) were   
chosen for further analysis. 
Table 2.  ADORA1 Gene Variants Found in the Japanese Population 
Location  Variants  rs#   SNP Name  Function 
IVS1A+182 G/T rs56298433      intron 
Exon2+363 T/G rs10920568    805T/G  synonymous  (Ala->Ala) 
IVS2+35826 T4/T5  rs5780149    intron 
Exon3+937 A/C  rs6427994    1777C/A  untranslated 
Exon3+987 C/T rs41264025    1827C/T  untranslated 
Exon3+1064 C/T  rs16851030    1904C/T  untranslated 
Exon3+1454 T/del  rs11315020    2294insT  untranslated 
The nucleotide sequence of the ADORA1 gene was referenecd to the NCBI nucleotide database under accession number AC105940. Exon numbers were based on the report by Ren 
and colleagues [17]. The column labelled rs# shows SNP numbers from the NCBI SNP database. The data in the column labelled SNP name are from the report by Deckert [20]. 
 
Table 3.  Genotypic and Allelic Distribution of the ADORA1 Gene SNPs in the METH Subjects and the Controls 
SNP  Group  N  Genotype (%)  P  Allele (%)  P 
      G  G/T  T     G  T     IVS1A+182 
(rs56298433)  Control  224  222 (99.1%)  2 (0.9%)  0 (0.0%)  446 (99.6%)  2 (0.4%) 
   METH  168  166 (98.8%)  2 (1.2%)  0 (0.0%) 
0.961 
334 (99.4%)  2 (0.6%) 
0.823 
      T  T/G  G     T  G     Exon2+363 
(rs10920568)  Control  229  162 (70.7%)  63 (27.5%)  4 (1.7%)  387 (84.5%)  71 (15.5%) 
   METH  171  132 (77.2%)  36 (21.1%)  3 (1.8%) 
0.333 
300 (87.7%)  42 (12.3%) 
0.233 
      T4  T4/T5  T5     T4  T5     IVS2+35826 
(rs5780149)  Control  229  150 (65.5%)  69 (30.1%)  10 (4.4%)  369 (80.6%)  89 (19.4%) 
   METH  171  108 (63.2%)  55 (32.2%)  8 (4.7%) 
0.887 
271 (79.2%)  71 (20.8%) 
0.708 
      A  A/C  C     A  C     Exon3+937 
(rs6427994)  Control  229  2 (0.9%)  46 (20.1%)  181 (79.0%)  50 (10.9%)  408 (89.1%) 
   METH  171  5 (2.9%)  38 (22.2%)  128 (74.9%) 
0.248 
48 (14.0%)  294 (86.0%) 
0.222 
      C  C/T  T     C  T     Exon3+987 
(rs41264025)  Control  229  215 (93.9%)  14 (6.1%)  0 (0.0%)  444 (96.9%)  14 (3.1%) 
   METH  171  162 (94.7%)  9 (5.3%)  0 (0.0%) 
0.937 
333 (97.4%)  9 (2.6%) 
0.888 
      C  C/T  T     C  T     Exon3+1064 
(rs16851030)  Control  229  89 (38.9%)  116 (50.7%)  24 (10.5%)  294 (64.2%)  164 (35.8%) 
   METH  171  80 (46.8%)  67 (39.2%)  24 (14.0%) 
0.071 
227 (66.4%)  115 (33.6%) 
0.572 
N: number of samples. 
P: Significance values between the METH subjects and the controls. 140    Current Neuropharmacology, 2011, Vol. 9, No. 1  Kobayashi et al. 
Relationship Between the ADORA1 Gene SNPs and 
METH Dependence/Psychosis 
  Association analyses between these SNPs in the 
ADORA1 gene and METH dependence/psychosis were per-
formed using DNA samples from 171 METH dependent/ 
psychotic subjects and 214 control subjects (Table 3). Among 
them, the genotypes of five control samples and three METH 
samples could not be determined at IVS1A+182 (rs56298433). 
The genotypic frequencies in these SNPs were within the 
Hardy-Weinberg expectations. No significant differences of 
the genotypic and allelic distributions of these SNPs in these 
samples were observed. As the minor allele frequencies   
of two SNPs, IVS1A+182 (rs56298433) and Exon3+987 
(rs41264025), were less than 5%, another four SNPs, Exon 
2+363 (rs10920568), IVS2+35826 (rs5780149), Exon3+937 
(rs6427994), and Exon3+1064 (rs16851030), were used for 
further analyses. 
  A global test of differentiation among samples based on 
haplotype frequencies was performed using the Arlequin 
program, but no significant association with METH depend-
ence/psychosis was observed (P=0.590). Haplotype frequen-
cies were estimated by the Arlequin program, and locus by 
locus LD was calculated by using the appropriate formula in 
the Excel program. Most of the SNPs in exon 2 and exon 3 
were in LD, suggesting that the locus from exon 2 to exon 3 
was in a LD block (Table 4).  
  Subcategory analyses were conducted on the clinical pa-
rameters (latency of psychosis, prognosis of psychosis, and 
spontaneous relapse) (Table 5). Significant differences were 
observed in the shorter latency of psychosis (P=0.025) at 
Exon3+937 (rs6427994). However, this significance disap-
peared after Bonferroni correction by the sub-group num-
bers, two (P < 0.025). 
DISCUSSION 
  We analyzed the ADORA1 gene variations in a Japanese 
population and found seven SNPs in exons and exon-intron 
boundaries. However, no significant associations were   
Table 4.  Linkage Disequilibrium Mapping of the ADORA1 Gene 
 
Exon2+363 
(rs10920568) 
IVS2+35826 
(rs5780149) 
Exon3+937 
(rs6427994) 
Exon3+1064  
(rs16851030) 
Exon2+363     0.807   0.729   0.374  
IVS2+35826  0.029      1.000   0.676  
Exon3+937  0.012   0.030      1.000  
Exon3+1064  0.014   0.061   0.068     
                                                   r
2 
  
  
D' 
  
D' and r
2 values for Controls are shown in the upper right and lower left, respectively.  
 
Table 5.  Genotypic Distribution of the ADORA1 Gene SNPs in Subcategorized METH Subjects 
SNP  Exon2+363 (rs10920568)  IVS2+35826 (rs5780149)  Exon3+937 (rs6427994)  Exon3+1064 (rs16851030) 
 
Genotype T  T/G G   T4 T4/T5  T5   A A/C  C   C C/T T  
Group  N           P           P         P           P 
Control    229  162  63  4     150  69  10     2  46  181     89  116  24    
Latency of Psychosis                                                    
      <3 years  67  48  16  3  0.387   46 17 4  0.684    4 10 53 0.025  30 26 11  0.173 
3 years  71  56  15  0  0.275   40 29 2  0.229    0 22 49 0.124  35 28 8  0.237 
Prognosis of Psychosis                                                    
      Transient (<1 month)  91  70  19  2  0.465   59 29 3  0.883    3 22 66 0.190  42 37 12  0.269 
       Prolonged (1 month)  56 41  14  1  0.932    33 20 3  0.654    1 11 44 0.835  27 21 8  0.205 
Spontaneous Relapse                                                    
       Not present  104  81  22  1  0.381   64 34 6  0.733    4 25 75 0.107  52 39 13  0.081 
METH 
       Present  60  45  13  2  0.519   39 19 2  0.923    1 11 48 0.831  25 24 11  0.163 
N: number of samples.  
P: Significance values between the METH subjects and the controls. ADORA1 Gene Association with METH Abuse  Current Neuropharmacology, 2011, Vol. 9, No. 1    141 
observed between these SNPs and METH dependence/ 
psychosis in the genotypic, allelic, haplotypic or clinically 
subcategorized analyses. 
  This is the first association analysis between ADORA1 
gene variants and drug addiction. We failed to find associa-
tions between the ADORA1 gene SNPs and METH depend-
ence/psychosis. While the significant difference (P=0.025) in 
the shorter latency of psychosis at Exon3+937 (rs6427994) 
disappeared after Bonferroni correction, this may have been 
due to the sample size, and thus further analysis with a larger 
sample is warranted. 
  The variants we found were one synonymous SNP, two 
intron SNPs and four exon SNPs in the untranslated region. 
These SNPs are unlikely to affect receptor function because 
they are not non-synonymous SNPs or promoter SNPs. Be-
cause several animal studies have suggested a modulatory 
role of adenosine receptors for dopamine systems, it remains 
possible that another region in the ADORA1 gene, such as a 
promoter region or intron regions, contributes to the altera-
tion of ADORA1 gene function. 
  Although a few association analyses of the ADORA1 
gene and psychiatric diseases have been performed, no sig-
nificant association has been reported between ADORA1 
variants and bipolar affective disorder or panic disorder [20, 
21]. As caffeine is a nonselective adenosine receptor antago-
nist, the association between the psychoactive effects of caf-
feine and gene variants of adenosine receptors have also 
been studied. However, the anxiogenic response to an acute 
dose of caffeine in healthy, infrequent caffeine users was not 
associated with ADORA1 gene polymorphism [22]. Interin-
dividual variation in the anxiety response to amphetamine 
has also been studied in healthy volunteers, but no associa-
tion was observed with ADORA1 gene variants [23]. These 
results suggest that the ADORA1 gene variations have little 
effect on psychiatric symptoms and/or personality traits. 
  In conclusion, our data suggest that the ADORA1 gene 
variants may not play a major role in the development of 
METH dependence/psychosis. 
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